We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVA
76
Inventiva
IVA
$1.03B
$1.55M 0.27%
+334,251
New +$1.55M
ANNX icon
77
CALL
Annexon
ANNX
$854M
$1.55M 0.27%
+309,100
New +$1.18M
LEGN icon
78
CALL
Legend Biotech
LEGN
$3.69B
$1.5M 0.26%
+69,000
New +$1.98M
BCRX icon
79
BioCryst Pharmaceuticals
BCRX
$2.25B
$1.49M 0.26%
+190,928
New +$1.38M
ARDX icon
80
Ardelyx
ARDX
$1.22B
$1.47M 0.25%
252,198
-147,802
-37% -$823K
ASND icon
81
Ascendis Pharma A/S
ASND
$16.1B
$1.46M 0.25%
6,840
-20,732
-75% -$4.28M
AQST icon
82
CALL
Aquestive Therapeutics
AQST
$478M
$1.36M 0.23%
+211,100
New +$1.32M
XERS icon
83
Xeris Biopharma Holdings
XERS
$1.39B
$1.34M 0.23%
170,568
+95,815
+128% +$754K
RIGL icon
84
Rigel Pharmaceuticals
RIGL
$680M
$1.28M 0.22%
+30,000
New +$1.13M
SLNO
85
DELISTED
Soleno Therapeutics
SLNO
$1.25M 0.21%
26,892
-150,438
-85% -$8.25M
PCRX icon
86
Pacira BioSciences
PCRX
$1.04B
$1.24M 0.21%
48,025
-10,901
-18% -$259K
TRVI icon
87
Trevi Therapeutics
TRVI
$2.54B
$1.22M 0.21%
97,184
+11,354
+13% +$131K
MPLT
88
MapLight Therapeutics
MPLT
$560M
$1.12M 0.19%
+63,791
New +$1.07M
QURE icon
89
uniQure
QURE
$3.02B
$1.08M 0.19%
+45,000
New +$1.74M
PCVX icon
90
Vaxcyte
PCVX
$7.82B
$1.06M 0.18%
22,972
-195,313
-89% -$8.74M
ENTA icon
91
Enanta Pharmaceuticals
ENTA
$368M
$1.03M 0.18%
+65,138
New +$827K
PRTA icon
92
Prothena Corp
PRTA
$433M
$1.02M 0.18%
+106,539
New +$1.08M
GLUE icon
93
Monte Rosa Therapeutics
GLUE
$1.32B
$977K 0.17%
+62,281
New +$839K
DSGN icon
94
Design Therapeutics
DSGN
$794M
$941K 0.16%
+100,320
New +$786K
INO icon
95
Inovio Pharmaceuticals
INO
$57.6M
$929K 0.16%
+533,682
New +$1.18M
MLYS icon
96
Mineralys Therapeutics
MLYS
$2.25B
$907K 0.16%
+25,000
New +$1M
MREO
97
CALL
Mereo BioPharma
MREO
$52.8M
$833K 0.14%
1,999,500
+479,300
+32% +$912K
KOD icon
98
CALL
Kodiak Sciences
KOD
$2.54B
$828K 0.14%
29,600
+1,800
+6% +$36.9K
AYTU icon
99
AYTU BioPharma
AYTU
$24.3M
$795K 0.14%
305,788
+33,118
+12% +$74.3K
EOLS icon
100
CALL
Evolus
EOLS
$394M
$790K 0.14%
+118,800
New +$805K
2 3
4
5 6

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.